PAR:OSE

OSE Immunotherapeutics S.A. · PAR · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-08 12:42 UTC

Last close

n/aEUR

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-1439.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
-1303.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed

Growth is the furthest below its sector's middle: 0.07 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.14x

5.94x

6.44x

1.41x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.14x
Its own average over 10 years, 18.7M.
Profit5.94x
Its own average over 10 years, -6.3M.
Free cash flow6.44x
Its own average over 10 years, -5.3M.
Debt1.41x
Its own average over 10 years, 25.1M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 6.44 times.

Sales is 0.14 times its own 10-year average; Profit is 5.94 times its own 10-year average; Free cash flow is 6.44 times its own 10-year average; Debt is 1.41 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average0.14
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Profit against its own 10-year average5.94
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Free cash flow against its own 10-year average6.44
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Debt against its own 10-year average1.41
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
EUR